Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc. -- Ignore unavailable to you. Want to Upgrade?

To: russet who wrote (69)	4/17/2002 1:53:49 PM
From: geoffb_si	Read Replies (1) \| Respond to of 103

My bags are packed, too...CEOCast interview of Brad Thompson released today: ceocast.com Contains: - Summary of Reovirus - Quick review of Phase I results - Overview of Glioblastoma; dose escalation phase - Patient enrollment for Glioblastoma (expects quick enrollment, and finished with study by early 2003) - Overview of Prostate trial - Partnering; expects to have a partner before going into Pivotal trials; value of partnership to ONC is highest when there is SOME Phase II data. - Systemic administration; currently in design phase. All pre-clinical (animal) work is complete. Expects to file application for this study some time this year. 3 studies concurrent by end of year. - Cash: burn-rate is low; approximately 2 years of capital; clinical studies DON'T cost a lot; manufacturing is cheap. Probably a financing some time in the future, after Phase II results (?). - Animal use: probably off-label. Data ONC have seen suggests there is a role for Reolysin in animal use, but only after approved for human use. - Expecting to report in next year: Interim results in Prostate, Glioblastoma, Systemic ("barrage of clinical information"), potential of a partnership agreement. Regards, Geoff